Efficacy and safety of pentosan polysulfate sodium in people with symptomatic knee osteoarthritis and dyslipidaemia: protocol of the MaRVeL trial
https://pubmed.ncbi.nlm.nih.gov/38777590/
ACTRN12621000654853
A Double-Blind, RandoMised, Placebo-Controlled Study to Assess the
Efficacy and Safety of oRal deliVery of sodium Pentosan Polysulfate (PPS)
compared to placebo in participants with symptomatic kneE osteoarthritis
(OA) and dysLipidemia (MaRVeL Study)
https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12621000654853
Name
Arthropharm Pty Ltd
https://www.arthropharm.com.au/
- Forums
- ASX - By Stock
- PAR
- research reports and media
research reports and media, page-4100
-
- There are more pages in this discussion • 204 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
|
|||||
Last
28.5¢ |
Change
-0.005(1.72%) |
Mkt cap ! $99.69M |
Open | High | Low | Value | Volume |
29.0¢ | 29.0¢ | 28.5¢ | $34.79K | 121.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 70181 | 28.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
29.0¢ | 10000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 70181 | 0.280 |
2 | 41363 | 0.275 |
6 | 42930 | 0.270 |
5 | 56200 | 0.265 |
8 | 52551 | 0.260 |
Price($) | Vol. | No. |
---|---|---|
0.290 | 10000 | 1 |
0.305 | 50000 | 1 |
0.310 | 52457 | 2 |
0.315 | 20507 | 3 |
0.320 | 65687 | 4 |
Last trade - 14.42pm 24/07/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online